Australian Market Community

HealthCo Healthcare & Wellness REIT (ASX:HCW) · Community narrative · July 2026 My fair value: A$1.07–1.13 (exit-adjusted) · Buy under A$0.68 · Current price A$0.72 The one-line thesis The market is pricing HCW as though its hospital income is permanently halved. The evidence says the damage is 10–15% — and that gap, not the rent, is the entire return on offer.Read more

Cobram Estate Olives isn’t just a familiar supermarket bottle—it controls its own groves in Australia and the US, which helps it avoid the cost shocks that hit many rivals. A big US deal could boost its scale in a fast-growing market, but expectations are already high and water costs and easing global olive oil prices could quickly expose any misstep.Read more

Macquarie’s latest results show a broad-based lift across all its major divisions, with much of its income coming from outside Australia, which can help soften bumps in the local economy. The key question is whether steadier parts of the business can keep offsetting the more unpredictable swings in markets, commodities, and one-off asset sales.Read more

Perpetual is reshaping itself by selling its Wealth Management arm and using the cash to pay down debt, which could leave a simpler business that some buyers already seem interested in. But the upside depends on approvals, smooth separation work, and whether markets and client money flows cooperate once the deal closes.Read more

Karoon Energy throws off a lot of cash from its offshore oil fields, but investors have soured after equipment problems and worries about rising spending. If taking direct control of its key production vessel really improves reliability and costs, the market’s gloomy view could prove too harsh.Read more

A once-popular Australian investment company has fallen out of favour as more investors shift to simpler, lower-fee options, leaving its shares trading below what its holdings appear to be worth. The appeal is a steady stream of cash payouts that could matter more if markets deliver weaker returns—though those payouts may rely on past wins and the manager still has to earn its keep.Read more

Medibank looks like a steady, well-run health insurer with a loyal customer base and strong cash generation, but the market already treats it like a “safe” pick. The bigger question is what could actually push returns higher from here—and whether regulation and ongoing fallout from the cyber breach could spoil the story.Read more

A long-troubled energy developer suddenly looks very different after wiping out its debt and agreeing to sell unused power turbines for a huge cash payout. The big question now is whether the buyer follows through on staged payments—and whether management uses the windfall to finish a key gas terminal and reward shareholders or repeats past mistakes.Read more

A little-known Australian miner says it could become one of the few reliable sources of hard-to-get rare earths outside China—materials used in electric vehicles, wind turbines, and defense equipment. A government-mandated sell-down has been weighing on the shares, but once that clears, upcoming final project decisions and potential government-backed funding could change the story fast.Read more